ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MRNA | MODERNA INC | Healthcare | $93.61B | 15.29% |
2HUM | HUMANA INC | Healthcare | $53.29B | 8.70% |
3VEEV | VEEVA SYSTEMS INC | Healthcare | $48.96B | 8.00% |
4NTRA | NATERA INC | Healthcare | $46.83B | 7.65% |
5IQV | IQVIA HOLDINGS INC | Healthcare | $44.68B | 7.30% |
6ILMN | ILLUMINA INC | Healthcare | $31.68B | 5.18% |
7GH | GUARDANT HEALTH INC | Healthcare | $20.95B | 3.42% |
8RVTY | REVVITY INC | Healthcare | $17.53B | 2.86% |
9CRL | CHARLES RIVER LABORATORIES INTERNATIONAL INC | Healthcare | $16.33B | 2.67% |
10GKOS | GLAUKOS CORP | Healthcare | $14.56B | 2.38% |
11HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 1.87% |
12OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 1.62% |
13HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 1.61% |
14TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 1.59% |
15CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 1.32% |
16TXG | 10X GENOMICS INC | Healthcare | $7.77B | 1.27% |
17KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 1.24% |
18AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 1.24% |
19TWST | TWIST BIOSCIENCE CORP | Healthcare | $7.16B | 1.17% |
20CAI | CARIS LIFE SCIENCES INC | Healthcare | $6.87B | 1.12% |
21KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 1.11% |
22HAE | HAEMONETICS CORP | Healthcare | $5.59B | 0.91% |
23GRAL | GRAIL INC | Healthcare | $5.46B | 0.89% |
24CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $5.44B | 0.89% |
25LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $5.38B | 0.88% |
26HTFL | HEARTFLOW INC | Healthcare | $5.21B | 0.85% |
27ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $4.77B | 0.78% |
28OPCH | OPTION CARE HEALTH INC | Healthcare | $4.75B | 0.78% |
29DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.52B | 0.74% |
30CDNA | CAREDX INC | Healthcare | $4.19B | 0.68% |
31PLSE | PULSE BIOSCIENCES INC | Healthcare | $3.84B | 0.63% |
32AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $3.84B | 0.63% |
33ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 0.62% |
34IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $3.53B | 0.58% |
35SGRY | SURGERY PARTNERS INC | Healthcare | $3.48B | 0.57% |
36VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $3.46B | 0.57% |
37XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $3.04B | 0.50% |
38XNCR | XENCOR INC | Healthcare | $2.86B | 0.47% |
39ATRC | ATRICURE INC | Healthcare | $2.85B | 0.47% |
40MBX | MBX BIOSCIENCES INC | Healthcare | $2.71B | 0.44% |
41PGNY | PROGYNY INC | Healthcare | $2.69B | 0.44% |
42AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.67B | 0.44% |
43SDGR | SCHRODINGER INC | Healthcare | $2.32B | 0.38% |
44NEO | NEOGENOMICS INC | Healthcare | $2.14B | 0.35% |
45BHVN | BIOHAVEN LTD | Healthcare | $2.13B | 0.35% |
46REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.34% |
47TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Healthcare | $2.05B | 0.33% |
48MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.33% |
49SEPN | SEPTERNA INC | Healthcare | $1.99B | 0.33% |
50FTRE | FORTREA HOLDINGS INC | Healthcare | $1.94B | 0.32% |
51AZTA | AZENTA INC | Healthcare | $1.92B | 0.31% |
52AGL | AGILON HEALTH INC | Healthcare | $1.85B | 0.30% |
53CERT | CERTARA INC | Healthcare | $1.82B | 0.30% |
54ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.29% |
55PSNL | PERSONALIS INC | Healthcare | $1.72B | 0.28% |
56NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.28% |
57SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.26% |
58ABSI | ABSCI CORP | Healthcare | $1.57B | 0.26% |
59AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.24% |
60DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.23B | 0.20% |
61NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.19% |
62SIBN | SI-BONE INC | Healthcare | $1.09B | 0.18% |
63VSTM | VERASTEM INC | Healthcare | $1.06B | 0.17% |
64BBNX | BETA BIONICS INC | Healthcare | $898M | 0.15% |
65HSTM | HEALTHSTREAM INC | Healthcare | $867M | 0.14% |
66RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $860M | 0.14% |
67KIDS | ORTHOPEDIATRICS CORP | Healthcare | $851M | 0.14% |
68VREX | VAREX IMAGING CORP | Healthcare | $769M | 0.13% |
69NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.11% |
70SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.10% |
71TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.09% |
72RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.08% |
73CARL | CARLSMED INC | Healthcare | $474M | 0.08% |
74MASS | 908 DEVICES INC | Healthcare | $407M | 0.07% |
75FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.06% |
76TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.06% |
77AGEN | AGENUS INC | Healthcare | $311M | 0.05% |
78TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.05% |
79SMTI | SANARA MEDTECH INC | Healthcare | $299M | 0.05% |
80QTTB | Q32 BIO INC | Healthcare | $264M | 0.04% |
81AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.03% |
82ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.03% |
83BDSX | BIODESIX INC | Healthcare | $109M | 0.02% |
84CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.02% |
85RLYB | RALLYBIO CORP | Healthcare | $84M | 0.01% |
86ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.01% |
87NTRB | NUTRIBAND INC | Healthcare | $73M | 0.01% |
88ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $612.18B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 93% toward Large, 78% toward Growth. +6% unclassified (12 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 88 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 88 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 17.7% | 5.2% |
| 3 yearsp.a. | 24.4% | 4.7% |
| 5 yearsp.a. | 12.9% | 8.4% |
| 10 yearsp.a. | 19.7% | 12.4% |
| Since inceptionp.a. | 14.6% | 3.9% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 23.4% | 12.0% |
| 2025 | 40.1% | 23.7% |
| 2024 | 10.3% | 4.2% |
| 2023 | -4.8% | -30.2% |
| 2022 | -4.2% | 30.7% |
| 2021 | 40.6% | 96.5% |
| 2020 | 51.0% | 16.1% |
| 2019 | 9.6% | -41.9% |
| 2018 | 4.1% | 31.8% |
| 2017 | 49.9% | 46.3% |
| 2016 | -14.6% | 12.8% |
| 2015 | 4.2% | -11.3% |
| 2014 | 13.6% | -14.5% |
| 2013 | 61.2% | 21.6% |
| 2012 | 13.9% | -11.1% |
| 2011 | 17.7% | 30.1% |
| 2010 | 11.3% | -11.2% |
| 2009 | 27.0% | -24.6% |
| 2008 | -14.9% | 3.5% |
| 2007 | 7.3% | -2.5% |
| 2006 | -1.8% | -14.9% |
| 2005 | 29.7% | 13.2% |
| 2004 | -2.7% | -15.3% |
| 2003 | 34.1% | -15.0% |
| 2002 | -34.4% | -17.2% |
| 2001 | -11.5% | 1.9% |
| 2000 | 16.8% | -13.9% |
| 1999 | 126.5% | 111.3% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare 6-Month Momentum Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 6-Month Momentum signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.